Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5185420
Max Phase: Preclinical
Molecular Formula: C22H23ClN2O3S
Molecular Weight: 430.96
Associated Items:
ID: ALA5185420
Max Phase: Preclinical
Molecular Formula: C22H23ClN2O3S
Molecular Weight: 430.96
Associated Items:
Canonical SMILES: O=C(O)Cc1cccc(OCCC2CCN(c3nc4ccc(Cl)cc4s3)CC2)c1
Standard InChI: InChI=1S/C22H23ClN2O3S/c23-17-4-5-19-20(14-17)29-22(24-19)25-9-6-15(7-10-25)8-11-28-18-3-1-2-16(12-18)13-21(26)27/h1-5,12,14-15H,6-11,13H2,(H,26,27)
Standard InChI Key: XGKJALQUHAMQNR-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 430.96 | Molecular Weight (Monoisotopic): 430.1118 | AlogP: 5.26 | #Rotatable Bonds: 7 |
Polar Surface Area: 62.66 | Molecular Species: ACID | HBA: 5 | HBD: 1 |
#RO5 Violations: 1 | HBA (Lipinski): 5 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 1 |
CX Acidic pKa: 4.04 | CX Basic pKa: 2.47 | CX LogP: 5.48 | CX LogD: 2.49 |
Aromatic Rings: 3 | Heavy Atoms: 29 | QED Weighted: 0.55 | Np Likeness Score: -1.67 |
1. Kato T, Ohara T, Suzuki N, Muto S, Tokuyama R, Mizutani M, Fukasawa H, Matsumura KI, Itai A.. (2022) Discovery and structure-based design of a new series of potent and selective PPARδ agonists utilizing a virtual screening method., 59 [PMID:35063634] [10.1016/j.bmcl.2022.128567] |
Source(1):